KR19990022137A - ２-(１ｈ-４(５)-이미다조일) 시클로프로필 유도체 - Google Patents

２-(１ｈ-４(５)-이미다조일) 시클로프로필 유도체

Info

Publication number
KR19990022137A
KR19990022137A KR1019970708616A KR19970708616A KR19990022137A KR 19990022137 A KR19990022137 A KR 19990022137A KR 1019970708616 A KR1019970708616 A KR 1019970708616A KR 19970708616 A KR19970708616 A KR 19970708616A KR 19990022137 A KR19990022137 A KR 19990022137A
Authority
KR
South Korea
Prior art keywords
imidazoyl
pharmaceutically acceptable
compound
cyclopropanamide
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019970708616A
Other languages
English (en)
Korean (ko)
Inventor
제임스 지. 필립스
클라크 이. 테드포드
아민 모하메드 칸
스티븐 엘. 예이츠
Original Assignee
로버트 씨. 에이. 프레드릭슨
글리아테크 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 씨. 에이. 프레드릭슨, 글리아테크 인코퍼레이티드 filed Critical 로버트 씨. 에이. 프레드릭슨
Publication of KR19990022137A publication Critical patent/KR19990022137A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Paints Or Removers (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
KR1019970708616A 1995-05-30 1996-05-29 ２-(１ｈ-４(５)-이미다조일) 시클로프로필 유도체 Ceased KR19990022137A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/453,359 US5652258A (en) 1995-05-30 1995-05-30 2-(4-imidazoyl) cyclopropyl derivatives
US8/453,359 1995-05-30

Publications (1)

Publication Number Publication Date
KR19990022137A true KR19990022137A (ko) 1999-03-25

Family

ID=23800267

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970708616A Ceased KR19990022137A (ko) 1995-05-30 1996-05-29 ２-(１ｈ-４(５)-이미다조일) 시클로프로필 유도체

Country Status (17)

Country Link
US (2) US5652258A (enExample)
EP (1) EP0837679B1 (enExample)
JP (1) JP2001503013A (enExample)
KR (1) KR19990022137A (enExample)
CN (1) CN1100534C (enExample)
AT (1) ATE207354T1 (enExample)
AU (1) AU713767B2 (enExample)
CA (1) CA2222101A1 (enExample)
DE (1) DE69616328T2 (enExample)
DK (1) DK0837679T3 (enExample)
ES (1) ES2163019T3 (enExample)
FI (1) FI974363L (enExample)
MX (1) MX9709211A (enExample)
NO (1) NO975484D0 (enExample)
NZ (1) NZ308410A (enExample)
PT (1) PT837679E (enExample)
WO (1) WO1996038141A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
US6008240A (en) * 1997-12-15 1999-12-28 Gliatech, Inc. 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6114350A (en) * 1999-04-19 2000-09-05 Nen Life Science Products, Inc. Cyanine dyes and synthesis methods thereof
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6794405B2 (en) 2000-08-17 2004-09-21 Merck & Co., Inc. Alicyclic imidazoles as H3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
AU2003248584A1 (en) * 2002-03-01 2003-09-16 Warner-Lambert Company Llc Method of treating osteoarthritis
CA2555071A1 (en) * 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
WO2005082893A2 (en) 2004-02-25 2005-09-09 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
MXPA06011167A (es) 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
US7696234B2 (en) 2004-06-02 2010-04-13 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
BRPI0514553A (pt) 2004-08-23 2008-06-17 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
WO2006044228A1 (en) 2004-10-18 2006-04-27 Eli Lilly And Company Histamine h3 receptor inhibitors, preparation and therapeutic uses
CA2600757C (en) 2005-03-17 2014-02-18 Eli Lilly And Company Pyrrolidine derivatives as histamine h3 receptor antagonists
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1868991B1 (en) 2005-04-01 2014-07-30 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
CA2622597A1 (en) * 2005-09-15 2007-03-22 Banyu Pharmaceutical Co., Ltd. Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder
EP1942104A1 (en) * 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
BR122019020471B1 (pt) * 2010-04-19 2021-06-22 Oryzon Genomics S.A. Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
UA116765C2 (uk) 2011-10-20 2018-05-10 Орізон Джіномікс, С.А. (гетеро)арилциклопропіламіни як інгібітори lsd1
CN104203914B (zh) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) * 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
ES2108107T3 (es) * 1991-02-27 1997-12-16 Seed Capital Investments Derivados de imidazol que tienen actividad antagonista en el receptor h3 de histamina.
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives

Also Published As

Publication number Publication date
EP0837679B1 (en) 2001-10-24
CN1192143A (zh) 1998-09-02
JP2001503013A (ja) 2001-03-06
US5990317A (en) 1999-11-23
DK0837679T3 (da) 2002-02-11
DE69616328T2 (de) 2002-07-04
FI974363A7 (fi) 1997-11-28
ATE207354T1 (de) 2001-11-15
ES2163019T3 (es) 2002-01-16
AU5804796A (en) 1996-12-18
FI974363A0 (fi) 1997-11-28
DE69616328D1 (de) 2001-11-29
EP0837679A1 (en) 1998-04-29
FI974363L (fi) 1997-11-28
PT837679E (pt) 2002-03-28
NZ308410A (en) 2001-06-29
CN1100534C (zh) 2003-02-05
US5652258A (en) 1997-07-29
EP0837679A4 (en) 1999-03-03
AU713767B2 (en) 1999-12-09
CA2222101A1 (en) 1996-12-05
WO1996038141A1 (en) 1996-12-05
MX9709211A (es) 1998-07-31
NO975484D0 (no) 1997-11-28

Similar Documents

Publication Publication Date Title
KR19990022137A (ko) ２-(１ｈ-４(５)-이미다조일) 시클로프로필 유도체
KR19990022136A (ko) １ｈ-４(５)-치환 이미다졸 유도체
KR100341950B1 (ko) 뇌세포보호제
JP2002509908A (ja) アミノシクロヘキシルエーテル化合物およびその用途
US6448282B1 (en) 1H-4(5)-substituted imidazole derivatives
EP0841923B1 (en) 1h-4(5)-substituted imidazole derivatives
US6008240A (en) 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
JPH05262723A (ja) 新規ピロリジン化合物
FI89799C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 2,5-diazabicyklo/2.2.1/heptanderivat
JP2002500658A (ja) ２−アミノ−７−（１−置換−２−ヒドロキシエチル）−３，５−ジヒドロピロロ［３，２−ｄ］ピリミジン−４−オン
US6072057A (en) 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
CZ8197A3 (en) (1h-indol-4-yl)-piperidine- or tetrahydropyridine ethyl amines and -ethyl carboxamides and pharmaceutical composition containing thereof
RU2114828C1 (ru) Энантиомеры ароматических азотсодержащих производных и их соли с неорганическими или органическими кислотами и способ их получения
JP3007675B2 (ja) 新規なインドール誘導体
KR20020016938A (ko) 함질소화합물을 유효성분으로 하는 신경장해개선제
MXPA97009210A (en) Derivatives of imidazol ih-4 (5) -substitui
JPWO2001010433A1 (ja) 含窒素化合物を有効成分とする神経障害改善剤
ZA200307464B (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors.
NZ314062A (en) 4-[1-[2-(pyridin-2-ylaminopropyl)]-piperidin-4-yl]indole derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19971129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20010313

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030430

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20031117

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20030430

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I